• Welcome, Guest. Please login or register.
    May 30, 2020, 12:55:12 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal © A. Battaglia 2019





55292 Posts in 5909 Topics by 6204 Members
Latest Member: pareshdas1985

Forum Tip: 
You can now simply type thalpal.com into your browser and it will take you to this site. Tell your friends about this easy-to-remember name.
www.thalpal.com
« previous next »
Pages: 1 Go Down Print
Author Topic: Bluebird Trials for Gene Therapy are Commencing  (Read 4024 times)
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8656


Will thal rule you or will you rule thal?


« on: June 10, 2014, 06:54:59 PM »

Bluebird Bio is beginning trials for gene therapy in three locations in the US, and there is also a clinical site established in Australia, but they have not yet set up a trial, so no recruiting is taking place as of yet. They are already underway in France again and eventually expect to expand trials to Asia. I'd like to thank the people at Bluebird for supplying this information.


HGB-204 (“Northstar”) study:
·         Study website: http://www.northstarstudy.com
o   Frequently asked questions
o   Pre-screening tool to determine if patients meet basic eligibility requirements
·         ClinicalTrials.gov website: http://clinicaltrials.gov/show/NCT01745120
o   This shows that a clinical site in Oakland and a clinical site in Chicago are already actively recruiting
o   This also shows that a clinical site in Australia is active although not yet recruiting
o   This will be updated over time
·         No clinical data from this study will be presented at the EHA conference in Milan on June 14


HGB-205 study (based in France):
·         ClinicalTrials.gov website: http://clinicaltrials.gov/show/NCT02151526
·         Clinical data from the first two patients on this study will be presented at the EHA conference in Milan on June 14


Contacting bluebird bio:
·         For Beta Thalassemia patients or caregivers who are specifically interested in clinical studies:
o   Please feel free to contact: clinicaltrials@bluebirdbio.com
·         For Beta Thalassemia patients or caregivers who are *not* specifically interested in participating in clinical studies, but who would like to stay in touch with the company; who would like to receive updates about our progress; or who wish to receive information about patient-centric resources:
o   Please feel free to contact: patient.advocacy@bluebirdbio.com
Logged

Andy

All we are saying is give thals a chance.
Bostonian_04
Senior Member
****
Offline Offline

Location: Boston

Gender: Male
Posts: 392


« Reply #1 on: June 10, 2014, 08:47:43 PM »

This is a great news..i feel hopeful that another 5 to 10 yrs there will be a cure for thal. Praying for success for Bluebird.

Andy, any news from Errant Gene trial that is ongoing at Sloan?
Logged

Quis custodiet ipsos custodes ? - Plato
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8656


Will thal rule you or will you rule thal?


« Reply #2 on: June 10, 2014, 09:01:47 PM »

I know Sadelain presented new data in May and they will also be presenting in Chicago, but I have no information yet on what the new data showed. I feel that they could do a better job with public relations.
Logged

Andy

All we are saying is give thals a chance.
Canadian_Family
Supreme Member
*****
Offline Offline

Posts: 1064



« Reply #3 on: June 11, 2014, 08:14:13 AM »

bluebird bio to present initial clinical data from its HGB-205 Study in beta-thalassemia major patients at the 19th European Hematology Association Congress on June 14, 2014. For details, please see link below.

Summary of Abstract Data and Clinical Data to be Presented at EHA:
-Clinical data will be presented on two subjects with beta-thalassemia major (#1201 and #1202) transplanted with new lentiviral vector BB305 in the HGB-205 Study
-Vector copy number in the drug product for subjects 1201 and 1202 are 1.5 and 2.1 respectively; higher than the drug product vector copy numbers reported in the prior LG001 Study (0.3-0.6), which used the older lentiviral vector HPV569
-A detailed update on the clinical data and transfusion status of subjects 1201 and 1202 will be provided as part of the EHA presentation
 
http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=1933355&highlight=
Logged

Regards.
Sharmin
Global Moderator
Supreme Member
*****
Offline Offline

Location: Canada

Gender: Female
Posts: 4155


Little A


« Reply #4 on: June 11, 2014, 09:58:53 AM »

Thank you for sharing this information Andy.  Thank you also for the update Canadian Family. 
I am praying that gene therapy will be safe and successful in treating thalassemia within the next few years. 

Sharmin
Logged

Sharmin
Bostonian_04
Senior Member
****
Offline Offline

Location: Boston

Gender: Male
Posts: 392


« Reply #5 on: June 11, 2014, 12:47:50 PM »

Thank you Andy, Thank you Canadian Family for all the information. Hope "no news is good news" from Dr. Sadelain's team...if any one of you go to Chicago conference, please share what you learn. All these trials are very encouraging ...
Logged

Quis custodiet ipsos custodes ? - Plato
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!